The Gamma Hydroxybutyric Acid in Alcohol-dependence Treatment Efficacy (GATE) I Trial: a Comparative Study Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome
Benzodiazepines (BDZs) are the gold standard in the treatment of alcohol withdrawal syndrome (AWS). Gamma-Hydroxybutyric acid also known as sodium oxybate (SMO) has been tested as a treatment for AWS with encouraging results. Aim of this phase IV, multicenter randomized double-blind, double dummy study is to evaluate the efficacy of SMO in comparison to oxazepam in the treatment of alcohol withdrawal symptoms (AWS).
100 Clinical Results associated with CT Pharmaceutical Industries, Sanremo - Italy
0 Patents (Medical) associated with CT Pharmaceutical Industries, Sanremo - Italy
100 Deals associated with CT Pharmaceutical Industries, Sanremo - Italy
100 Translational Medicine associated with CT Pharmaceutical Industries, Sanremo - Italy